Your prescription drug costs in California could drop significantly starting in 2026. On October 11, 2025, Governor Gavin Newsom signed California Department of Managed Health Care (DMHC), these practices contribute to California’s prescription drug spending, which exceeds $30 billion annually. SB-41 aims to reclaim billions in hidden costs.
What SB-41 Actually Changes (Starting 2026)
The law imposes four major requirements on PBMs operating in California:
| Requirement | What It Means for You |
|---|---|
| Fiduciary Duty | PBMs must act in your health plan’s best interest, not their own profits. Eliminates legal conflicts of interest. |
| 100% Rebate Pass-Through | All manufacturer rebates go directly to health plans, potentially lowering your premiums by 5-12% according to industry estimates. |
| Spread Pricing Ban | PBMs can’t mark up pharmacy costs. Health plans pay actual pharmacy rates plus transparent fees. |
| DMHC Licensing & Audits | Regular state audits ensure compliance. Violations can result in license suspension or fines. |
The DMHC will conduct annual audits of PBM contracts and pricing structures. PBMs that fail to comply risk losing their California operating license—a death sentence for companies doing business in the nation’s largest state market.
Here’s the timeline: PBMs have until January 1, 2026 to revise all existing contracts with California health plans. Any contract signed after October 11, 2025 must already comply with SB-41 requirements.
How This Hits Your Prescription Costs
Lower premiums sound great. But will you actually see savings?
Industry analysts predict a 7-15% reduction in employer health plan costs within two years of implementation. For California families paying an average $7,800 annually in health insurance premiums (per Kaiser Family Foundation data), that translates to $550–$1,170 in potential annual savings.
Out-of-pocket prescription costs could drop even more dramatically. The 100% rebate pass-through means your health plan receives full manufacturer discounts, which should flow to lower copays and coinsurance rates. For specialty medications—think insulin, cancer drugs, or biologics—where rebates can reach 40-60% of list price, the impact could be substantial.
However, three factors could limit immediate savings:
- Contract renegotiation lag: Health plans won’t see rebate benefits until 2026 contract renewals complete, potentially delaying premium adjustments to 2027 plan years.
- PBM fee increases: Some PBMs may raise transparent administrative fees to offset lost spread pricing revenue, though these fees face DMHC scrutiny.
- Market consolidation concerns: Smaller PBMs might exit California due to compliance costs, reducing competition and potentially limiting innovation in pharmacy benefits.
The DMHC will publish annual reports starting in 2027 showing actual cost impacts. Consumer advocates recommend comparing your 2026 and 2027 health plan costs carefully to verify promised savings materialize.
California Sets a National Precedent
Twenty-three states currently regulate PBMs in some form, but California’s law goes further than any existing legislation. The fiduciary duty requirement, in particular, breaks new ground—treating PBMs like financial advisors who must put clients first by law.
Ohio banned spread pricing in Medicaid contracts back in 2018, reporting $240 million in annual savings. Arkansas implemented similar reforms in 2019. But California represents the first comprehensive regulation of commercial insurance PBMs, not just government programs.
Watch these states closely in 2026-2027:
- New York: Legislature proposed nearly identical PBM fiduciary duty bills in 2024, stalled in committee but likely to revive with California’s success story.
- Texas: State insurance commissioner called for PBM transparency reforms in August 2025, citing California as a model.
- Illinois and Washington: Both states have active PBM reform coalitions backed by employer groups and patient advocacy organizations.
The National Association of Insurance Commissioners (NAIC) formed a PBM working group in September 2025 to develop model legislation based on California’s approach. If adopted, this could create nationwide standards by 2028.
Federal action remains uncertain. The Federal Trade Commission launched a PBM industry investigation in 2022, but Congress has yet to pass comprehensive reform legislation despite bipartisan support.
What PBMs Are Saying (And Not Saying)
Major PBM industry groups haven’t issued detailed public responses to SB-41 since Newsom’s signature. That silence speaks volumes—vocal opposition typically precedes legislative votes, not post-signing commentary.
Behind closed doors, PBM executives reportedly focus on three arguments:
- Administrative complexity: Revising thousands of contracts by 2026 requires significant systems upgrades and legal review, potentially costing tens of millions per company.
- Rebate negotiation impact: PBMs argue their ability to negotiate large rebates depends on flexibility to use those rebates strategically, not immediate pass-through requirements.
- Market exit concerns: Smaller regional PBMs may lack resources to comply, reducing competition and service options for California health plans.
The three largest PBMs—CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth Group)—control roughly 80% of the U.S. market. All three operate extensively in California and have sufficient scale to absorb compliance costs. Smaller competitors face tougher decisions.
Industry insiders predict 3-5 regional PBMs will exit California by mid-2026 rather than undergo expensive contract restructuring for relatively small state revenue.
Should You Switch Health Plans in 2026?
Maybe. But not immediately.
Your current health plan’s 2026 rates were likely set before SB-41 passed, meaning initial premium changes won’t reflect the new law’s savings. The real comparison comes during 2027 open enrollment when plans incorporate full-year data under new PBM contracts.
Smart moves for California health plan members:
- Request PBM transparency: Ask your health plan which PBM they use and whether their 2026 contract complies with SB-41 fiduciary requirements. Plans must disclose this information under California insurance law.
- Compare 2026 vs. 2027 premiums: Document your 2026 costs (premiums, deductibles, copays) and compare against 2027 offerings. Savings should appear in year two.
- Check formulary changes: Some PBMs might restructure drug formularies during contract renegotiations. Verify your current medications remain covered at similar cost-sharing levels.
- Monitor specialty drug costs: High-cost medications see the largest rebates, so specialty drug copays should drop more significantly than generic drug costs.
Employer-sponsored health plans have more immediate leverage. HR departments can demand SB-41-compliant contracts now, even before the January 2026 deadline, potentially capturing savings in 2026 plan years.
Frequently Asked Questions
When do California PBM regulations take effect?
SB-41 took effect immediately when Governor Newsom signed it on October 11, 2025. However, PBMs have until January 1, 2026 to revise existing contracts. New contracts signed after October 11, 2025 must comply immediately. Most consumers will see cost impacts in 2027 health plan rates.
How much will my prescriptions cost under the new law?
Industry estimates suggest 7-15% reductions in overall health plan costs, which should translate to lower premiums and copays. Specialty medications with high manufacturer rebates (40-60% of list price) could see larger decreases. Actual savings vary by health plan and drug. The DMHC will publish annual cost impact reports starting in 2027.
Does SB-41 apply to Medicare and Medicaid plans?
SB-41 primarily regulates commercial health insurance plans. Medicare Part D plans follow federal regulations set by the Centers for Medicare & Medicaid Services (CMS). California Medicaid (Medi-Cal) managed care plans fall under state DMHC oversight and likely must comply, though specific Medi-Cal implementation guidance is pending.
Can PBMs still make money under fiduciary duty rules?
Yes. PBMs can charge transparent administrative fees for services like claims processing, formulary management, and pharmacy network administration. The DMHC will audit these fees for reasonableness. What PBMs cannot do: keep rebates, charge spread pricing markups, or prioritize self-owned pharmacies without disclosure and justification.
Will other states copy California’s PBM law?
Very likely. The National Association of Insurance Commissioners formed a working group in September 2025 to develop model legislation based on SB-41. States including New York, Texas, Illinois, and Washington have active PBM reform efforts. If California demonstrates significant cost savings by 2027, expect 10-15 states to adopt similar laws by 2029.
The Bottom Line
California’s SB-41 fundamentally restructures how pharmacy benefit managers operate, shifting from profit-maximizing middlemen to fiduciary partners legally obligated to prioritize health plan interests. The 100% rebate pass-through and spread pricing ban could save California families hundreds to over a thousand dollars annually in health costs.
But don’t expect overnight miracles. Contract transitions take time, and health plans need a full year of data under new PBM agreements before passing savings to consumers through lower 2027 premiums. The DMHC’s enforcement rigor will determine whether PBMs comply in spirit or find regulatory workarounds.
For now, California residents should monitor their health plan communications closely, compare costs during 2027 open enrollment, and advocate for transparency if savings don’t materialize. This law only works if consumers hold health plans and regulators accountable for delivering promised cost reductions.
Other states, meanwhile, would be wise to watch California’s implementation closely. If the law delivers even half its projected savings, expect a national wave of PBM reform legislation by decade’s end. Your prescription costs might finally drop—but only if regulators and consumers demand it.